Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab in Advanced Endometrial Cancer
NCT03526432Phase 2Active, not recruiting
- Sponsor
- University of Oklahoma
- Start
- Aug 2018
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in endometrial cancer (EC), sponsored by University of Oklahoma. Started Aug 2018; status: active, not recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03526432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526432.